Sam Brusco, Associate Editor07.18.23
Stereotaxis, a company developing surgical robotics for minimally invasive endovascular intervention, announced the first patient were successfully treated using Abbott’s EnSite X EP system with its robotic magnetic navigation system.
Combining Abbott’s cardiac mapping system with Stereotaxis’ robotic tech brings together detailed, real-time diagnostic info with robotic precision and stability during therapy delivery. Integration of these technologies was first revealed at Heart Rhythm 2023.
The first procedures were performed by Dr. Sing-Chien Yap and Dr. Tamas Szili-Torok at Erasmus Medical Center in Rotterdam, The Netherlands, and by Dr. Burkhard Hügl at Marienhaus St. Elisabeth Hospital in Neuwied, Germany.
“The integration of advanced mapping with the precision and safety of robotics helps provide the best therapy for patients and an enhanced workflow for physicians,” Dr. Sing-Chien Yap told the press. “These pioneering integrated robotic EnSite X procedures went very well, with successful treatment of patients with atrial and ventricular arrhythmias in a safe and efficient fashion.”
“We have long championed the benefits of open interoperability in electrophysiology as a way to pair the most suitable technologies for each patient,” added Dr. Tamas Szili-Torok. “Full integrated use of EnSite X with Stereotaxis robotic technology worked smoothly and we are delighted to contribute to this progress.”
“The community of physicians who are pioneering robotics in electrophysiology have long championed increased integrations,” said Dr. Burkhard Hügl. “The integration of both systems enables me to address the most complex arrhythmia patients. I am very pleased with this technological advance and the growing recognition that robotics plays an important role for the electrophysiology field.”
Combining Abbott’s cardiac mapping system with Stereotaxis’ robotic tech brings together detailed, real-time diagnostic info with robotic precision and stability during therapy delivery. Integration of these technologies was first revealed at Heart Rhythm 2023.
The first procedures were performed by Dr. Sing-Chien Yap and Dr. Tamas Szili-Torok at Erasmus Medical Center in Rotterdam, The Netherlands, and by Dr. Burkhard Hügl at Marienhaus St. Elisabeth Hospital in Neuwied, Germany.
“The integration of advanced mapping with the precision and safety of robotics helps provide the best therapy for patients and an enhanced workflow for physicians,” Dr. Sing-Chien Yap told the press. “These pioneering integrated robotic EnSite X procedures went very well, with successful treatment of patients with atrial and ventricular arrhythmias in a safe and efficient fashion.”
“We have long championed the benefits of open interoperability in electrophysiology as a way to pair the most suitable technologies for each patient,” added Dr. Tamas Szili-Torok. “Full integrated use of EnSite X with Stereotaxis robotic technology worked smoothly and we are delighted to contribute to this progress.”
“The community of physicians who are pioneering robotics in electrophysiology have long championed increased integrations,” said Dr. Burkhard Hügl. “The integration of both systems enables me to address the most complex arrhythmia patients. I am very pleased with this technological advance and the growing recognition that robotics plays an important role for the electrophysiology field.”